Podocyte protection by darbepoetin: Preservation of the cytoskeleton and nephrin expression

Kidney International

Volumn 72, Issue 4, 2007, Pages 455-463

  Eto, N ^a   Wada, T ^a   Inagi, R ^a   Takano, H ^a   Shimizu, A ^b   Kato, H ^a   Kurihara, H ^c   Kawachi, H ^d   Shankland, S J ^e   Fujita, T ^a   Nangaku, M ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

^d NIIGATA UNIVERSITY   (Japan)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Acidosis; Aldosterone; Epithelial; Intracellular pH

Indexed keywords

B7 ANTIGEN; DESMIN; NEPHRIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PUROMYCIN AMINONUCLEOSIDE;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSKELETON; DRUG EFFECT; ELECTRON MICROSCOPY; HEMATOCRIT; HEMODILUTION; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; MALE; NEPHROTIC SYNDROME; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION;

ACTINS; ANIMALS; ANTIGENS, CD80; APOPTOSIS; CELLS, CULTURED; CYTOSKELETON; DESMIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; IN SITU NICK-END LABELING; MALE; MEMBRANE PROTEINS; NEPHROTIC SYNDROME; PODOCYTES; PROTECTIVE AGENTS; PROTEINURIA; PUROMYCIN AMINONUCLEOSIDE; RATS; RATS, WISTAR; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, ERYTHROPOIETIN; RNA, MESSENGER; TIME FACTORS;

EID: 34547815735     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002311     Document Type: Article

References (51)

1. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147.
2. Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol 2002; 13: 3005-3015.
3. Ryan GB, Karnovsky MJ. An ultrastructural study of the mechanisms of proteinuria in aminonucleoside nephrosis. Kidney Int 1975; 8: 219-232.
4. Caulfield JP, Reid JJ, Farquhar MG. Alterations of the glomerular epithelium in acute aminonucleoside nephrosis. Evidence for formation of occluding junctions and epithelial cell detachment. Lab Invest 1976; 34: 43-59.
5. Whiteside CI, Cameron R, Munk S et al. Podocytic cytoskeletal disaggregation and basement-membrane detachment in puromycin aminonucleoside nephrosis. Am J Pathol 1993; 142: 1641-1653.
6. Kubosawa H, Kondo Y. Modulation of cytoskeletal organization of podocytes during the course of aminonucleoside nephrosis in rats. Pathol Int 1994; 44: 578-586.
7. Doublier S, Salidiov G, Lupia E et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52: 1023-1030.
8. Langham RG, Kelly DJ, Cox AJ et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002; 45: 1572-1576.
9. Wernerson A, Duner F, Pettersson E et al. Altered ultrastructural distribution of nephrin in minimal change nephrotic syndrome. Nephrol Dial Transplant 2003; 18: 70-76.
10. Nangaku M, Eckard KU. Pathogenesis of renal anemia. Semin Nephrol 2006; 26: 261-268.
11. Fliser D, Bahlmann FH, Haller H. EPO: renoprotection beyond anemia correction. Pediatr Nephrol 2006; 21: 1785-1789.
12. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005; 293: 90-95.
13. Sharples EJ, Yaqoob MM. Erythropoietin in experimental acute renal failure. Nephron Exp Nephrol 2006; 104: e83-e88.
14. Chatterjee PK. Pleiotropic renal actions of erythropoietin. Lancet 2005; 365: 1890-1892.
15. Bahlmann FH, Song R, Boehm SM et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110: 1006-1012.
16. Bahlmann FH, DeGroot K, Duckert T et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 2003; 64: 1648-1652.
17. Floege J, Alpers CE, Sage EH et al. Markers of complement-dependent and complement-independent glomerular visceral epithelial cell injury in vivo. Expression of antiadhesive proteins and cytoskeletal changes. Lab Invest 1992; 67: 486-497.
18. Reiser J, von Gersdorff G, Loos M et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004; 113: 1390-1397.
19. Gwinner W, Landmesser U, Brandes RP et al. Reactive oxygen species and antioxidant defense in puromycin aminonucleoside glomerulopathy. J Am Soc Nephrol 1997; 8: 1722-1731.
20. Vega-Warner V, Ransom RF, Vincent AM et al. Induction of antioxidant enzymes in murine podocytes precedes injury by puromycin aminonucleoside. Kidney Int 2004; 66: 1881-1889.
21. Smoyer WE, Ransom RF. Hsp27 regulates podocyte cytoskeletal changes in an in vitro model of podocyte process retraction. FASEB J 2002; 16: 315-326.
22. Kestila M, Lenkkeru U, Mannikko M et al. Positionally cloned gene for a novel glomerular protein-nephrin is mutated in congenital nephrotic syndrome. Molecular Cell 1998; 1: 572-582.
23. Saleem MA, Ni L, Witherden I et al. Co-localization of nephrin, podocin, and the actin cytoskeleton: evidence for a role in podocyte foot process formation. Am J Pathol 2002; 161: 1459-1466.
24. Kawachi H, Koike H, Kurihara H et al. Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states. Kidney Int 2000; 57: 1949-1961.
25. Kawachi H, Koike H, Kurihara H et al. Cloning of rat homologue of podocin: expression in proteinuric states and in developing glomeruli. J Am Soc Nephrol 2003; 14: 46-56.
26. Shibata S, Nagase M, Fujita T. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 2006; 17: 754-764.
27. Ransom RF, Lam NG, Hallett MA et al. Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int 2005; 68: 2473-2483.
28. Koshikawa M, Mukoyama M, Mori K et al. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 2005; 16: 2690-2701.
29. Echigoya MH, Obikane K, Nakashima T et al. Glomerular localization of erythropoietin receptor mRNA and protein in neonatal and mature mouse kidney. Nephron Exp Nephrol 2005; 100: e21-e29.
30. Kawakami M, Sekiguchi M, Sato K et al. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 2001; 276: 39469-39475.
31. Chong ZZ, Li F, Maiese K. Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. Histol Histopathol 2005; 20: 299-315.
32. Cenni V, Sirri A, Riccio M et al. Targeting of the Akt/PKB kinase to the actin skeleton. Cell Mol Life Sci 2003; 60: 2710-2720.
33. Vandermoere F, Yazidi-Belkoura IE, Demont Y et al. Proteomics exploration reveals that actin is a signaling target of the kinase Akt. Mol Cell Proteomics 2007; 6: 114-124.
34. Qian Y, Corum L, Meng Q et al. PI3K induced actin filament remodeling through Akt and p70S6K1: implication of essential role in cell migration. Am J Physiol Cell Physiol 2004; 286: C153-C163.
35. Sakanaka M, Wen TC, Matsuda S et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998; 95: 4635-4640.
36. Sharples EJ, Patel N, Brown P et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004; 15: 2115-2124.
37. Leist M, Ghezzi P, Grasso G et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305: 239-242.
38. Fiordaliso F, Chimenti S, Staszewsky L et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 2005; 102: 2046-2051.
39. Bellizzi V, Sabbatini M, Fuiano G et al. The impact of early normalization of haematocrit by erythropoietin on renal damage in the remnant kidney model. Nephrol Dial Transplant 1998; 13: 2210-2215.
40. Kuriyama S, Tomonari H, Yoshida H et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-185.
41. Silverberg DS, Wexler D, Blum M et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003; 18: 141-146.
42. Tapolyai M, Kadomatsu S, Perera-Chong M. r.hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline. BMC Nephrol 2003; 4: 3.
43. Dean BB, Dylan M, Gano Jr A et al. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005; 21: 981-987.
44. Gouva C, Nikolopoulos P, Ioannidis JP et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-760.
45. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25.
46. Hertel JE, Locay HR, Scarlata DS et al. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease. Mayo Clin Proc 2006; 81: 1188-1194.
47. Noiri E, Nagano N, Negishi K et al. Efficacy of darbepoetin in doxorubicin-induced cardiorenal injury in rats. Nephron Exp Nephrol 2006: 104.
48. Belayev L, Khoutorova L, Zhao W et al. Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats. Stroke 2005; 36: 1071-1076.
49. Lipsic E, van der Meer P, Voors AA et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drug Ther 2006; 20: 135-141.
50. Kawachi H, Koike H, Kurihara H et al. Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states. Kidney Int 2000; 57: 1949-1961.
51. Yaoita E, Kurihara H, Sakai T et al. Phenotypic modulation of parietal epithelial cells of Bowman's capsule in culture. Cell Tissue Res 2001; 304: 339-349.